# A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

> **NCT02725957** · PHASE1 · COMPLETED · sponsor: **Bioblast Pharma Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteer Subjects

## Interventions

- **DRUG:** Trehalose for IV Infusion
- **DRUG:** Saline 0.9% IV

## Key facts

- **NCT ID:** NCT02725957
- **Lead sponsor:** Bioblast Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2016-06
- **Final completion:** 2016-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02725957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02725957, "A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02725957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*